Article Impact Level: HIGH Data Quality: STRONG Summary of Stroke, https://doi.org/10.1161/STROKEAHA.125.052146 Dr. Joseph P. Broderick et al.
Points
- A workshop discussed AI and novel trial designs for acute ischemic stroke on March 28, 2025.
- AI’s role in stroke imaging is significant and is poised to expand considerably in clinical care and research.
- Human oversight and quality data are essential for maximizing AI’s effectiveness in clinical practice and trials.
- Platform trials address multiple questions simultaneously by sharing controls, increasing efficiency but potentially complexity.
- Future stroke trials should incorporate pragmatic and patient-centered designs to assess effectiveness in routine care.
Summary
A workshop convened by the Stroke Treatment Academic Industry Roundtable XIII on March 28, 2025, addressed the integration of artificial intelligence (AI) and innovative clinical trial designs for acute ischemic stroke. The forum brought together a diverse group of stroke physicians, researchers, and industry representatives to discuss both current applications and future opportunities in this evolving field. While AI currently plays a significant role in acute stroke treatment, particularly in imaging, its impact is anticipated to expand considerably in clinical care and research trials in the coming years. Maximizing AI’s effectiveness will necessitate careful attention to data quality and understanding used for training, along with a crucial “human in the loop” element involving clinicians and trialists at the bedside.
The workshop also highlighted the utility of novel trial designs, specifically platform trials. These trials are structured to address multiple scientific questions within a single framework by sharing control groups across various interventions. This approach is expected to enhance efficiency and potentially reduce the time required to answer critical clinical questions, although it may introduce complexities into standard workflows. The discussion emphasized the importance of incorporating elements of pragmatic and patient-centered trial design into future acute ischemic stroke clinical trials whenever feasible. Pragmatic trials, by design, evaluate treatment effectiveness within routine clinical care settings rather than under idealized conditions, offering more real-world applicability.
In conclusion, AI models, alongside platform, pragmatic, and patient-centered trial designs, represent powerful new tools for addressing important clinical questions in acute ischemic stroke. A thorough understanding of their operational mechanisms, optimal applications, and inherent limitations is paramount. Such comprehensive knowledge will be critical for accelerating the successful development and implementation of new treatments, ultimately improving outcomes for stroke patients.
Link to the article: https://www.ahajournals.org/doi/10.1161/STROKEAHA.125.052146
References
Broderick, J. P., Mistry, E. A., Wechsler, P. M., Elkind, M. S. V., Liebeskind, D. S., Harston, G., Wolenberg, J., Frontera, J. A., Kimberly, W. T., Favilla, C. G., Boltze, J., Ospel, J., Samaniego, E. A., Adeoye, O., Kasner, S. E., Schwamm, L. H., Albers, G. W., Bolanos, O., Campbell, B. C. V., … Wakhloo, A. K. (2025). Artificial intelligence and novel trial designs for acute ischemic stroke: Opportunities and challenges. Stroke, STROKEAHA.125.052146. https://doi.org/10.1161/STROKEAHA.125.052146
